Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 16 (15), 3819-21

Killing the Killer: Natural Killer Cells to Treat Ewing's Sarcoma

Affiliations
Review

Killing the Killer: Natural Killer Cells to Treat Ewing's Sarcoma

Yong-Oon Ahn et al. Clin Cancer Res.

Abstract

Cho and coworkers show that Ewing's sarcoma cells are highly sensitive to expanded allogeneic natural killer (NK) cells, partially through a NKG2D- and DNAM-1-dependent mechanism. Using an orthotopic murine model, they also show that irradiation significantly enhances the NK-cell killing of these tumors.

Figures

Figure 1
Figure 1. Conceptualized Schema of NK Cell Therapy For Patients With Ewing’s Sarcoma
Peripheral blood lymphocytes are collected from a healthy donor. The NK cells are expanded over 2–3 weeks using the K562-feeder cell line (K562-mb15-41BBL) and low dose IL-2 (left). The patient receives irradiation therapy to the site(s) of disease, which increases the expression of NKG2D ligands. The infused NK cells traffic to the sites of disease and kill the tumor tissue.

Comment on

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles
Feedback